|
US5164410A
(en)
|
1988-01-09 |
1992-11-17 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
PH26256A
(en)
|
1988-08-12 |
1992-04-01 |
Fujisawa Pharmaceutical Co |
Oxaspiro [2,5] octane derivative
|
|
US5166172A
(en)
|
1988-09-01 |
1992-11-24 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
KR0138530B1
(en)
|
1988-09-01 |
1998-05-15 |
우메모또 요시마사 |
Fumagillol derivatives
|
|
US5180738A
(en)
|
1988-09-01 |
1993-01-19 |
Takeda Chemical Industries |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
EP0387650B1
(en)
|
1989-03-06 |
1993-03-31 |
Takeda Chemical Industries, Ltd. |
6-epifumagillols, production and use thereof
|
|
US5288722A
(en)
|
1989-03-06 |
1994-02-22 |
Takeda Chemical Industries, Ltd. |
6-amino-6-desoxyfumagillols, production and use thereof
|
|
US5290807A
(en)
|
1989-08-10 |
1994-03-01 |
Children's Medical Center Corporation |
Method for regressing angiogenesis using o-substituted fumagillol derivatives
|
|
US6017954A
(en)
|
1989-08-10 |
2000-01-25 |
Children's Medical Center Corp. |
Method of treating tumors using O-substituted fumagillol derivatives
|
|
EP0415294A3
(en)
|
1989-08-31 |
1991-06-12 |
Takeda Chemical Industries, Ltd. |
Cyclohexanol derivatives, production and use thereof
|
|
TW282399B
(en)
|
1990-05-25 |
1996-08-01 |
Takeda Pharm Industry Co Ltd |
|
|
US5238950A
(en)
|
1991-12-17 |
1993-08-24 |
Schering Corporation |
Inhibitors of platelet-derived growth factor
|
|
ATE205092T1
(en)
|
1992-01-30 |
2001-09-15 |
Takeda Chemical Industries Ltd |
METHOD FOR PRODUCING HIGHLY WATER SOLUBLE CYCLODEXTRIN COMPLEXES
|
|
ATE153854T1
(en)
|
1992-12-16 |
1997-06-15 |
Takeda Chemical Industries Ltd |
STABLE PHARMACEUTICAL PREPARATION CONTAINING FUMAGILLOL DERIVATIVES
|
|
EA000150B1
(en)
|
1995-03-27 |
1998-10-29 |
Санофи |
Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections and pharmaceutical base thereof
|
|
US6180626B1
(en)
|
1995-10-11 |
2001-01-30 |
Fujisawa Pharmaceutical Co., Ltd. |
Vascular-permeability suppressants
|
|
EP0799616A1
(en)
|
1996-04-01 |
1997-10-08 |
Takeda Chemical Industries, Ltd. |
Oral composition comprising a fumagillol derivative
|
|
WO1998005293A2
(en)
|
1996-08-02 |
1998-02-12 |
The Children's Medical Center Corporation |
Method of regulating the female reproductive system through angiogenesis inhibitors
|
|
US6281245B1
(en)
|
1996-10-28 |
2001-08-28 |
Versicor, Inc. |
Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
|
|
US7115632B1
(en)
|
1999-05-12 |
2006-10-03 |
G. D. Searle & Co. |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
|
DK0973392T3
(en)
|
1997-03-04 |
2004-03-29 |
Monsanto Co |
Divalent sulfonyl-aryl or heteroaryl hydroxamic acid compounds
|
|
US6207704B1
(en)
|
1997-06-09 |
2001-03-27 |
Massachusetts Institute Of Technology |
Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
|
|
DE69824750T2
(en)
|
1997-10-31 |
2005-07-07 |
Children's Medical Center Corp., Boston |
METHODS FOR REGULATING THE SIZE AND GROWTH OF A BLOODED NORMAL TISSUE
|
|
AU1529799A
(en)
|
1997-12-23 |
1999-07-12 |
Warner-Lambert Company |
Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
|
|
US6242494B1
(en)
|
1998-05-01 |
2001-06-05 |
Abbott Laboratories |
Substituted β-amino acid inhibitors of methionine aminopeptidase-2
|
|
KR100357542B1
(en)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
Fumagillol derivatives and preparation method thereof
|
|
KR100357541B1
(en)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
5-Demthoxyfumagillol derivatives and processes for preparing the same
|
|
JP2000116337A
(en)
|
1998-10-09 |
2000-04-25 |
Nippon Shokuhin Kako Co Ltd |
Pet food
|
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
|
NZ515087A
(en)
|
1999-04-28 |
2003-11-28 |
Aventis Pharma Gmbh |
Tri-aryl acid derivatives as PPAR receptor ligands
|
|
WO2001024796A1
(en)
|
1999-10-01 |
2001-04-12 |
Smithkline Beecham Corporation |
1,2,4-triazole derivatives, composition, process of making and methods of use
|
|
US20020002152A1
(en)
|
2000-04-14 |
2002-01-03 |
Craig Richard A. |
Hydrazide and alkoxyamide angiogenesis inhibitors
|
|
US6323228B1
(en)
|
2000-09-15 |
2001-11-27 |
Abbott Laboratories |
3-substituted indole angiogenesis inhibitors
|
|
PE20020376A1
(en)
|
2000-09-29 |
2002-05-13 |
Abbott Lab |
ANTIANGIOGENIC POLYPEPTIDES AND METHODS TO INHIBIT ANGIOGENESIS
|
|
EP1330447A2
(en)
|
2000-11-01 |
2003-07-30 |
Praecis Pharmaceuticals Incorporated |
Peptides as met-ap2 inhibitors
|
|
US6548477B1
(en)
|
2000-11-01 |
2003-04-15 |
Praecis Pharmaceuticals Inc. |
Therapeutic agents and methods of use thereof for the modulation of angiogenesis
|
|
EE200300303A
(en)
|
2000-12-20 |
2003-12-15 |
Bristol-Myers Squibb Company |
Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
|
|
JP2004525942A
(en)
|
2001-03-29 |
2004-08-26 |
スミスクライン・ビーチャム・コーポレイション |
Compounds and methods
|
|
US20020183242A1
(en)
|
2001-04-11 |
2002-12-05 |
Jack Henkin |
Peptide antiangiogenic drugs
|
|
EP1436286B1
(en)
|
2001-09-27 |
2009-08-19 |
Equispharm Co., Ltd. |
Fumagillol derivatives and preparing method thereof
|
|
US6803382B2
(en)
|
2001-11-09 |
2004-10-12 |
Galderma Research & Development, S.N.C. |
Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
|
|
US7119120B2
(en)
|
2001-12-26 |
2006-10-10 |
Genzyme Corporation |
Phosphate transport inhibitors
|
|
KR100451485B1
(en)
|
2002-03-28 |
2004-10-06 |
주식회사종근당 |
Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same
|
|
US6989392B2
(en)
|
2002-06-18 |
2006-01-24 |
Abbott Laboratories |
2-Aminoquinolines as melanin concentrating hormone receptor antagonists
|
|
US7030262B2
(en)
|
2002-08-06 |
2006-04-18 |
Abbott Laboratories |
3-Amino-2-hydroxyalkanoic acids and their prodrugs
|
|
US20040067266A1
(en)
|
2002-10-07 |
2004-04-08 |
Toppo Frank R. |
Weight loss compound
|
|
US20040068012A1
(en)
|
2002-10-08 |
2004-04-08 |
Comess Kenneth M. |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US20040157836A1
(en)
|
2002-10-08 |
2004-08-12 |
Comess Kenneth M. |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US7491718B2
(en)
|
2002-10-08 |
2009-02-17 |
Abbott Laboratories |
Sulfonamides having antiangiogenic and anticancer activity
|
|
WO2004078113A2
(en)
|
2003-03-04 |
2004-09-16 |
Pharmacia Corporation |
Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
|
|
DE602004015614D1
(en)
|
2003-08-08 |
2008-09-18 |
Janssen Pharmaceutica Nv |
2- (CHINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS
|
|
AR046330A1
(en)
|
2003-09-09 |
2005-12-07 |
Japan Tobacco Inc |
DIPEPTIDILPEPTIDASA IV INHIBITOR
|
|
ES2295973T3
(en)
|
2003-12-22 |
2008-04-16 |
Memory Pharmaceuticals Corporation |
INDOLES, 1H-INDAZOLES, 1,2-BENCISOXAZOLES, AND 1,2-BENCISOTIAZOLES, AND PREPARATION AND USES OF THE SAME.
|
|
JP2007537147A
(en)
|
2003-12-29 |
2007-12-20 |
プレーシス ファーマスーティカルズ インコーポレイテッド |
Inhibitors of methionine aminopeptidase-2 and uses thereof
|
|
KR100552043B1
(en)
|
2004-02-28 |
2006-02-20 |
주식회사종근당 |
Composition for obesity treatment comprising fumagillol derivatives
|
|
JP2007537275A
(en)
|
2004-05-12 |
2007-12-20 |
ケモセントリックス， インコーポレイテッド |
Arylsulfonamide
|
|
CA2571683A1
(en)
|
2004-06-30 |
2006-01-12 |
Combinatorx, Incorporated |
Methods and reagents for the treatment of metabolic disorders
|
|
US20060045865A1
(en)
|
2004-08-27 |
2006-03-02 |
Spherics, Inc. |
Controlled regional oral delivery
|
|
AU2005289887A1
(en)
|
2004-09-24 |
2006-04-06 |
Janssen Pharmaceutica, N.V. |
Sulfonamide compounds
|
|
EP1841761A4
(en)
|
2005-01-26 |
2008-10-29 |
Chong Kun Dang Pharm Corp |
Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
|
|
FR2886855B1
(en)
|
2005-06-08 |
2009-07-17 |
Agronomique Inst Nat Rech |
USE OF FUMAGILLIN AND ITS DERIVATIVES TO INCREASE BIODAVAILABILITY OF MACROCYLIC LACTONES
|
|
US20070078172A1
(en)
|
2005-06-16 |
2007-04-05 |
Jenrin Discovery |
Mao-b inhibitors useful for treating obesity
|
|
WO2007076348A2
(en)
|
2005-12-23 |
2007-07-05 |
Smithkline Beecham Corporation |
Azaindole inhibitors of aurora kinases
|
|
TW200815405A
(en)
|
2006-06-09 |
2008-04-01 |
Astrazeneca Ab |
Novel compounds
|
|
WO2008008374A2
(en)
|
2006-07-14 |
2008-01-17 |
Chemocentryx, Inc. |
Ccr2 inhibitors and methods of use thereof
|
|
DE102007020492A1
(en)
|
2007-04-30 |
2008-11-06 |
Grünenthal GmbH |
Substituted sulfonamide derivatives
|
|
PE20090720A1
(en)
|
2007-05-24 |
2009-06-11 |
Wyeth Corp |
DERIVATIVES OF AZACICLYLBENZAMIDE AS ANTAGONISTS OF HISTAMINE-3
|
|
JP2010531896A
(en)
|
2007-06-26 |
2010-09-30 |
チルドレンズ メディカル センター コーポレーション |
MetAP-2 inhibitor polymersomes for therapeutic administration
|
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
|
MX2010005857A
(en)
|
2007-11-28 |
2010-11-22 |
Mersana Therapeutics Inc |
Biocompatible biodegradable fumagillin analog conjugates.
|
|
PL2227466T3
(en)
|
2007-11-30 |
2011-09-30 |
Bayer Ip Gmbh |
Heteroaryl-substituted piperidines
|
|
CA2731020A1
(en)
|
2008-07-18 |
2010-01-21 |
Zafgen, Inc. |
Use of antiangiogenic fumagillins in the treatment of obesity
|
|
CN102239149B
(en)
|
2008-10-06 |
2015-05-13 |
约翰·霍普金斯大学 |
Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
|
|
US8906896B2
(en)
|
2008-10-24 |
2014-12-09 |
Ulrich Bierbach |
Platinum acridine anti-cancer compounds and methods thereof
|
|
WO2010065879A2
(en)
*
|
2008-12-04 |
2010-06-10 |
Zafgen Corporation |
Methods of treating an overweight or obese subject
|
|
US20120004162A1
(en)
|
2008-12-04 |
2012-01-05 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
WO2010065883A2
(en)
|
2008-12-04 |
2010-06-10 |
Zafgen Corporation |
Method of treating an overweight or obese subject
|
|
US20120010259A1
(en)
|
2008-12-04 |
2012-01-12 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
AU2010303270A1
(en)
|
2009-10-09 |
2012-05-03 |
Zafgen Corporation |
Sulphone compounds for use in the treatment of obesity
|
|
US8815309B2
(en)
|
2010-01-08 |
2014-08-26 |
Zafgen, Inc. |
Methods of treating a subject with benign prostate hyperplasia
|
|
US20130023513A1
(en)
|
2010-01-12 |
2013-01-24 |
Hughes Thomas E |
Methods and Compositions for Treating Cardiovascular Disorders
|
|
US20130210821A1
(en)
|
2010-05-27 |
2013-08-15 |
James E. Vath |
Methods for Treating Obesity
|
|
US20120020647A1
(en)
|
2010-07-21 |
2012-01-26 |
Rovi Technologies Corporation |
Filtering repeated content
|
|
US9266896B2
(en)
|
2010-07-22 |
2016-02-23 |
Zafgen, Inc. |
Tricyclic compounds and methods of making and using same
|
|
US8428080B2
(en)
|
2010-09-16 |
2013-04-23 |
Apple Inc. |
Method to control reconfiguration of multiple radio access bearers in a wireless device
|
|
WO2012051318A1
(en)
|
2010-10-12 |
2012-04-19 |
Zafgen Corporation |
Sulphonamide compounds and methods of making and using same
|
|
CA2817199C
(en)
|
2010-11-09 |
2019-01-15 |
Zafgen, Inc. |
Crystalline solids of a metap-2 inhibitor and methods of making and using same
|
|
WO2012064928A1
(en)
|
2010-11-10 |
2012-05-18 |
Zafgen Corporation |
Methods and compositions for treating thyroid hormone related disorders
|
|
WO2012074968A1
(en)
|
2010-11-29 |
2012-06-07 |
Zafgen Corporation |
Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
|
|
WO2012103333A1
(en)
|
2011-01-26 |
2012-08-02 |
Zafgen Corporation |
Tetrazole compounds and methods of making and using same
|
|
BR112013028665A2
(en)
|
2011-05-06 |
2016-09-06 |
Zafgen Inc |
tricyclic sulfonamide compounds and methods for making and using them
|
|
CA2835261C
(en)
|
2011-05-06 |
2019-06-04 |
Zafgen, Inc. |
Partially saturated tricyclic compounds and methods of making and using same
|
|
BR112013028666A2
(en)
|
2011-05-06 |
2017-08-08 |
Zafgen Inc |
tricyclic pyrazolo sulfonamide compounds and methods for making and using the same
|
|
WO2013033430A1
(en)
|
2011-09-02 |
2013-03-07 |
Wake Forest School Of Medicine |
Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
|
|
JP2015509102A
(en)
|
2012-01-18 |
2015-03-26 |
ザフゲン，インコーポレイテッド |
Tricyclic sulfone compounds and methods for making and using the same
|
|
JP6035347B2
(en)
|
2012-01-18 |
2016-11-30 |
ザフゲン，インコーポレイテッド |
Tricyclic sulfonamide compounds and methods for making and using the same
|
|
JP2015536981A
(en)
|
2012-11-05 |
2015-12-24 |
ザフゲン，インコーポレイテッド |
Tricyclic compounds and methods for their production and use
|
|
AU2013337288A1
(en)
|
2012-11-05 |
2015-05-21 |
Zafgen, Inc. |
Tricyclic compounds for use in the treatment and/or control of obesity
|
|
SG11201503521QA
(en)
|
2012-11-05 |
2015-06-29 |
Zafgen Inc |
Methods of treating liver diseases
|